作者: L Zlatohlávek , M Vrablík , M Prusíková , M Šnejdrlová
DOI: 10.33549/PHYSIOLRES.931860
关键词: Endocrinology 、 Polyunsaturated fatty acid 、 Clinical endpoint 、 Disease 、 Internal medicine 、 Medicine 、 Bioinformatics 、 Epidemiology 、 Clinical trial 、 Arterial stiffness 、 Risk assessment 、 Evidence-based medicine
摘要: There is a large body of evidence documenting the effects long-chain polyunsaturated fatty acids with first double bond at third position from methyl-terminal (so called omega-3 (FAs)) on different components cardiovascular disease (CVD) risk. However, it may seem more answers topic we learn, questions remain to be elucidated. are three levels impact fish FAs CVD Epidemiological data have shown unequivocally increased intake associated lower morbidity and mortality. Numerous experimental studies (almost always) positive lipoprotein metabolism, coagulation platelet function, endothelial arterial stiffness etc. Most importantly, there few prospective clinical endpoint trials (DART, JELIS, GISSI Prevenzione GISSI-HF) that examined supplementation outcomes in patient populations. Recent meta-analyses these other yielded somewhat conflicting results. In this review will summarize current risk focusing new recent as well possible practical implications for practice.